Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
16°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
93.39
+1.80 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
Via
InvestorPlace
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...
Via
Talk Markets
3 Dividend Stocks That Are No-Brainer Buys Right Now
February 24, 2024
These stocks check off multiple boxes for investors.
Via
The Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
February 24, 2024
This biotech stock could be poised for a nice rebound if analysts are right.
Via
The Motley Fool
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
February 23, 2024
Via
Benzinga
Is NASDAQ:GILD a Good Fit for Dividend Investing?
February 12, 2024
Analyzing GILEAD SCIENCES INC (NASDAQ:GILD)'s Dividend Potential.
Via
Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
February 07, 2024
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
February 20, 2024
These are the stocks to buy to unlock the secrets of market giants in various industries for monumental growth and returns.
Via
InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.
Via
InvestorPlace
Why Is Gilead Sciences Stock Trading Lower Today?
February 16, 2024
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials.
Via
Benzinga
Exposures
Product Safety
When you look at NASDAQ:GILD, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
February 16, 2024
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
February 14, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
February 13, 2024
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800...
Via
Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why is CymaBay (CBAY) Stock Up 25% Today?
February 12, 2024
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.
Via
InvestorPlace
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
February 12, 2024
Via
Benzinga
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue...
Via
Benzinga
Exposures
Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
February 12, 2024
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.
Via
Investor's Business Daily
Gilead Sciences Stock Approaches Daily Buying Area
February 12, 2024
Gilead Sciences, Inc. is an US American biopharmaceutical company. It focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and...
Via
Talk Markets
Exposures
COVID-19
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Top 5 Health Care Stocks That Are Preparing To Pump In February
February 09, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
February 08, 2024
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Why Gilead Sciences Stock Dropped Today
February 07, 2024
Gilead missed revenue estimates with its latest quarter and issued underwhelming 2024 guidance.
Via
The Motley Fool
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
February 07, 2024
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
February 07, 2024
These stocks aren't value traps.
Via
The Motley Fool
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
February 06, 2024
The Dow gained +141 points, +0.37%, while the S&P gained +0.23%. The Nasdaq, while positive, was essentially flat at +0.07%, while the small-cap Russell won the day, +0.85%, and continues inching its...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.